Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX · NASDAQ Global Select
-$0.15 today
Vol 2.64M · Avg 1.75M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-101.8%
avg -77.0%
ROIC
13.8%
avg 8.4%
ROA
2.0%
avg 2.5%
Analysis
ROIC is currently the strongest return metric at 13.8% versus its period average of 8.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Chintu Patel | Co-Founder, Co-CEO & Director | $1.76M | — | 54 | $1.64M | 0.52% |
Chirag K. Patel | Co-Founder, Co-CEO, President & Director | $1.72M | — | 59 | $1.64M | 0.52% |
Andrew S. Boyer | Executive Vice President and Chief Commercial Officer of Generics & Biosciences | $1.10M | — | 60 | $445,208.00 | 0.14% |
Anastasios G. Konidaris | Executive Vice President & Chief Financial Officer | $1.04M | — | 59 | $449,434.00 | 0.14% |
Jason Daly | Executive Vice President, Chief Legal Officer & Corporate Secretary | $947,942.00 | — | 52 | $71,760.00 | 0.02% |
Nikita Shah | Executive Vice President & Chief Human Resources Officer | $874,334.00 | — | 48 | $399,793.00 | 0.13% |
Stanley Fisher | Vice President & Head of Medical Affairs | — | — | — | — | — |
Srinivas Kone | Senior Vice President & Chief Scientific Officer of Generics | — | — | — | — | — |
Pranav Mehta | Senior Vice President of Strategic Sourcing & Supply Management | — | — | — | — | — |
Sanjay Kumar Jain | Chief Quality Officer | — | — | — | — | — |
Anthony DiMeo | Head/VP of Investor Relations | — | — | — | — | — |
Gregory Sgammato | Senior Vice President of Corporate Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
14
$12.97M
Net Sentiment
$12.97M
Net selling
Most Active
Shah Nikita
5 transactions
1–10 of 14
Analysis
Insiders reported 0 buys worth $0.00 and 14 sells worth $12.97M over the last 12 months. That adds up to net selling of $12.97M. Shah Nikita was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +24.3% | +7.9% (10yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +24.3% over three years. Forward estimates point to Revenue at +7.9% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Lantheus Holdings, Inc.
NASDAQ:LNTH
$6.79B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$5.30B
Indivior Pharmaceuticals Inc
NASDAQ:INDV
$4.77B
Envista Holdings Corp
NYSE:NVST
$4.18B
Telix Pharmaceuticals Limited
NASDAQ:TLX
$3.39B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.27B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.57B
Bausch Health Companies Inc.
NYSE:BHC
$1.74B
Perrigo Company plc
NYSE:PRGO
$1.37B
Who manages AMRX?
Amneal Pharmaceuticals, Inc. (AMRX) lists 12 active executives. The top listed executive is Anastasios G. Konidaris, Executive Vice President & Chief Financial Officer.
Are AMRX insiders buying or selling?
Recent insider activity shows net selling of $86.53M.
Explore More
Continue the stock analysis
Jump to another research area for this company.